An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)

被引：0
作者：
Johnston, P. B.
Lewis, L. T.
Rogerio, J. W.
机构：
[1] Mayo Clin Rochester, Rochester, MN USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps299
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS299
引用
收藏
页数：1
相关论文
共 50 条
[31]   Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study [J].
Zent, Clive S. ;
Bowen, Deborah A. ;
Conte, Michael J. ;
LaPlant, Betsy R. ;
Call, Timothy G. .
LEUKEMIA & LYMPHOMA, 2016, 57 (07) :1585-1591
[32]   A phase II, single-arm, open-label study of pralatrexate in patients with aggressive relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): Study PDX-015 [J].
Chang, J. E. ;
Rosen, P. J. ;
Diefenbach, C. S. Magid ;
Kacprowicz, H. ;
O'Connor, O. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[33]   A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-hodgkin lymphoma (NHL) [J].
Gornet, Michel K. ;
Habermann, Thomas M. ;
Ansell, Stephen M. ;
Micallef, Ivana N. ;
Porrata, Luis F. ;
Johnston, Patrick B. ;
Maurer, Matthew J. ;
LaPlant, Betsy ;
Kabat, Brian ;
Inwards, David J. ;
Colgan, Joseph P. ;
Call, Timothy ;
Markovic, Svetomir ;
Zent, Clive S. ;
Zeldenrust, Steven R. ;
Tun, Han W. ;
Witzig, Thomas E. .
BLOOD, 2007, 110 (11) :44A-44A
[34]   Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies [J].
Yee, Karen W. L. ;
Zeng, Zhihong ;
Konopleva, Marina ;
Verstovsek, Srdan ;
Ravandi, Farhad ;
Ferrajoli, Alessandra ;
Thomas, Deborah ;
Wierda, William ;
Apostolidou, Efrosyni ;
Albitar, Maher ;
O'Brien, Susan ;
Andreeff, Michael ;
Giles, Francis J. .
CLINICAL CANCER RESEARCH, 2006, 12 (17) :5165-5173
[35]   Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study [J].
Guenther, A. ;
Baumann, P. ;
Burger, R. ;
Klapper, W. ;
Schmidmaier, R. ;
Gramatzki, M. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[36]   A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China [J].
Zheng, Zhong ;
Zhang, Huilai ;
Wang, Jingwen ;
Zhou, Keshu ;
Zhang, Li ;
Zhou, Hui ;
Zhang, Qingyuan ;
Zhao, Weili .
BLOOD, 2021, 138
[37]   Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study [J].
You, Liangshun ;
Liu, Yi ;
Mai, Wenyuan ;
Xie, Wanzhuo ;
Zhou, De ;
Mao, Liping ;
Chen, Lili ;
Zhou, Xinping ;
Ma, Liya ;
Zheng, Xiaolong ;
Wei, Juying ;
Lou, Yinjun ;
Ye, Xingnong ;
Tong, Hongyan ;
Jin, Jie ;
Meng, Haitao .
EUROPEAN JOURNAL OF CANCER, 2024, 202
[38]   Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study [J].
Deng, Li-Juan ;
Zhou, Ke-Shu ;
Liu, Li-Hong ;
Zhang, Ming-Zhi ;
Li, Zhi-Ming ;
Ji, Chun-Yan ;
Xu, Wei ;
Liu, Ting ;
Xu, Bing ;
Wang, Xin ;
Gao, Su-Jun ;
Zhang, Hui-Lai ;
Hu, Yu ;
Li, Yan ;
Cheng, Ying ;
Yang, Hai-Yan ;
Cao, Jun-Ning ;
Zhu, Zun-Min ;
Hu, Jian-Da ;
Zhang, Wei ;
Jing, Hong-Mei ;
Ding, Kai-Yang ;
Zhang, Xiang-Yang ;
Zhao, Ren -Bin ;
Zhang, Bin ;
Tian, Ya -Min ;
Song, Yong-Ping ;
Song, Yu-Qin ;
Zhu, Jun .
BLOOD ADVANCES, 2023, 7 (16) :4349-4357
[39]   Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial [J].
Kroiss, Matthias ;
Quinkler, Marcus ;
Johanssen, Sarah ;
van Erp, Nielka P. ;
Lankheet, Nienke ;
Poellinger, Alexander ;
Laubner, Katharina ;
Strasburger, Christian J. ;
Hahner, Stefanie ;
Mueller, Hans-Helge ;
Allolio, Bruno ;
Fassnacht, Martin .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10) :3495-3503
[40]   An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma [J].
Xie, Y. ;
Mi, L. ;
Zheng, W. ;
Ping, L. ;
Lin, N. ;
Tu, M. ;
Zhang, C. ;
Ying, Z. ;
Liu, W. ;
Deng, L. ;
Wu, M. ;
Wang, X. ;
Zhu, J. ;
Song, Y. .
ANNALS OF ONCOLOGY, 2020, 31 :S652-S652
12345